Abstract 1686P
Background
As global cancer cases increase exponentially, the number of caregivers subsequently increases to support patients. Despite being indispensable, the available resource was reserved mainly for patients, undermining the importance of caregivers who also share the struggle and burden. The chronic amount of stress and responsibility that caregivers face leads to impairment of quality of life (QOL). Further, most research that assesses the QOL is mainly conducted in the developed countries with robust palliative care. This comparative study aims to map and explore the status quo of QOL levels from caregivers of cancer patients in Asia. In addition, to investigate the correlation of QOL impairments in caregivers with sociodemographic factors.
Methods
A comprehensive systematic review of the literature was performed through databases with the keywords “cancer”, “caregiver”,” quality of life”, and “Asia” spans from 2004-2024. 371 articles that satisfy eligible criteria were retrieved. A total of 1271 family caregivers for cancer patients who had taken outpatient treatment, finished sociodemographic, and the Caregiver Quality of Life Index-Cancer (CQOLC) survey were included. Gathered CQOLC total scores from 12 countries including Indonesia, Singapore, Malaysia, Turkey, Iran, Jordanian, India, South Korea, China, Taiwan, Japan, and Saudi Arabia dataset, were compared and analyzed for their correlation with sociodemographic factors.
Results
Different distributions of total scores of CQOLC in 12 Asia countries observed with higher CQOLC total scores were scored within the developed countries with mature palliative care systems. Further, varying caregiver determinants including different sociodemographic characteristics could produce impaired QOL such as male gender, parental relationships, certain ethnicity, and late-stage cancer.
Conclusions
Despite sharing cultural context and family-based caregivers, uneven QOL distribution was observed across Asian countries. This study also highlights the potential areas to be improved. Additionally, acknowledging the diversity of values, culture, and socio-demographics significantly helps in creating more optimal interventions to support caregivers.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1699P - Impact of Latino ethnicity on the gut microbiome and response to immune checkpoint inhibition (ICI) with CBM588 in patients (pts) with metastatic renal cell cancer (mRCC)
Presenter: Regina Barragan-Carrillo
Session: Poster session 11
1700P - Impact of sarcomatoid (S) and rhabdoid (R) components (comp.) on the efficacy of nivolumab (N) +/- ipilimumab (I) in the first-line (L1) treatment of metastatic clear cell renal cell carcinoma (mRCC) in the randomized phase II BIONIKK trial
Presenter: Yann-Alexandre Vano
Session: Poster session 11
1701P - NEOTAX: A phase II trial of neoadjuvant toripalimab plus axitinib for clear cell renal cell carcinoma with inferior vena cava tumor thrombus
Presenter: Liangyou Gu
Session: Poster session 11
1702P - Updated results of phase II study of cabozantinib (Cabo) with nivolumab (Nivo) and ipilimumab (Ipi) in advanced renal cell carcinoma with divergent histologies (RCCdh)
Presenter: Bradley McGregor
Session: Poster session 11
1703P - Updated overall survival in patients with prior checkpoint inhibitor (CPI) therapy in the phase III TIVO-3 study
Presenter: Miguel Zugman
Session: Poster session 11
1704P - Potential surrogate endpoints for overall survival (OS) in immunotherapy (IO)-treated metastatic renal cell carcinoma (mRCC): An International Metastatic Database Consortium (IMDC) study
Presenter: Renee Saliby
Session: Poster session 11
1705P - Association between baseline radiological tumor burden (BRTB) and outcomes in metastatic clear cell renal cell carcinoma (mccRCC) treated with first line (1L) immunotherapy (IO)-based regimens
Presenter: Rashad Nawfal
Session: Poster session 11
1707P - A plasma proteomic based algorithm is associated with prognosis in renal cell carcinoma
Presenter: Eddy Saad
Session: Poster session 11
1708P - The clinical value of tumor-informed minimal residual disease detection in renal cell carcinoma
Presenter: linhui wang
Session: Poster session 11